Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newlife to develop wristwatch heart rate monitor:

This article was originally published in Clinica

Executive Summary

US company Newlife Technologies is to use technology licensed from BTG International to develop a wristwatch-like device that can noninvasively monitor vital signs in the human body, such as heart rate. The technology consists of an optical fibre sensor that can pick up physiological changes in the body through the strap, Steve Burton, Newlife's president told Clinica. The Midlothian, Virginia-based company will use the technology to enhance its FDA-approved heart rate monitoring product, the HEARTalker, which vocally feeds back ECG measurements from a strap worn around the chest to assist the user during personal training.

You may also be interested in...



Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT070025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel